Abstract

Cancer is a disease of genome instability and genomic alterations; now, genomic heterogeneity is rapidly emerging as a defining feature of cancer, both within and between tumors. Motivation for our pilot study of tumor heterogeneity in esophageal squamous cell carcinoma (ESCC) is that it is not well studied, but the highest incidences of esophageal cancers are found in China and ESCC is the most common type. We profiled the mutations and changes in copy number that were identified by whole-exome sequencing and array-based comparative genomic hybridization in multiple regions within an ESCC from two patients. The average mutational heterogeneity rate was 90% in all regions of the individual tumors in each patient; most somatic point mutations were nonsynonymous substitutions, small Indels occurred in untranslated regions of genes, and copy number alterations varied among multiple regions of a tumor. Independent Sanger sequencing technology confirmed selected gene mutations with more than 88% concordance. Phylogenetic analysis of the somatic mutation frequency demonstrated that multiple, genomically heterogeneous divergent clones evolve and co-exist within a primary ESCC and metastatic subclones result from the dispersal and adaptation of an initially non-metastatic parental clone. Therefore, a single-region sampling will not reflect the evolving architecture of a genomically heterogeneous landscape of mutations in ESCC tumors and the divergent complexity of this genomic heterogeneity among patients will complicate any promise of a simple genetic or epigenetic diagnostic signature in ESCC. We conclude that any potential for informative biomarker discovery in ESCC and targeted personalized therapies will require a deeper understanding of the functional biology of the ontogeny and phylogeny of the tumor heterogeneity.

Highlights

  • Cancer is a disease of genome instability and a resulting accumulation of genetic and epigenetic alteration

  • To characterize the extent of intratumor genomic heterogeneity in Esophageal squamous cell carcinoma (ESCC), we performed whole-exome sequencing on four separate regions within a primary ESCC sample and a non-tumor region from adjacent normal tissue from two patients (Pt), denoted as patient A (PtA) and patient B (PtB) (Figures 1a and b, Supplementary Table S1)

  • PtA was diagnosed with ESCC without lymph node invasion, clinical stage was T2N0M0; PtB was diagnosed with advanced ESCC with lymph node metastasis, clinical stage was T3N2M0

Read more

Summary

Introduction

Cancer is a disease of genome instability and a resulting accumulation of genetic and epigenetic alteration. Accumulating evidence for intratumor heterogeneity[1,2,3,4,5,6] is showing that tumors evolve through a process of branched evolution with genetically distinct subclones, which lead to tumor recurrence, drug resistance and metastatic potential.[7,8]. To establish the framework for a comprehensive and systematic whole-genome analysis of ESCC, we conducted a pilot study in ESCC patients, using multipleregion, whole-exome sequencing and array-based comparative genomic hybridization (aCGH), applied to 11 tumor regions from two surgically resected ESCCs, including metastatic lymph nodes. We show here that each tumor region has substantial genomic heterogeneity with its own unique profile of mutations and copy number alterations. Functional analysis revealed common as well as unique, actionable and druggable mutated genes in the landscape of intratumor genomic heterogeneity in ESCC. We will suggest that targeting the gene regulatory networks, which underlie the fitness landscape of ESCC, with a Canada T2N 4N1

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call